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Introduction
Juvenile dermatomyositis (JDM) is a multisystem vascu-
lopathic disease characterized by muscle inflammation
that causes symmetrical muscle weakness. Assessment
of muscle strength is, therefore, a fundamental compo-
nent of the clinical evaluation of children with JDM.
This assessment is traditionally made using the 8-mus-
cle Manual Muscle Testing (MMT) and the Childhood
Myositis Assessment Scale (CMAS). However, the
MMT does not cover all muscles or muscle groups
affected in JDM, namely abdominal muscles. Although
the CMAS is more comprehensive than the MMT, it is
lengthy and, therefore, may not be feasible in a busy
clinical setting or when a physical therapist is not
available.
Objectives
The study aim was to investigate the construct validity
of a new hybrid measure of muscle strength, named
hybrid MMT/CMAS (hmc), developed by merging the
MMT with 3 items of the CMAS.
Methods
The hmc is composed of all 8 items of the MMT and the
following items of the CMAS: 1) head lift; 2) sits-ups; 3)
floor rise. Item 3) is recoded on 0 to 9 scale. The total
score of the hmc ranges from 0 (worst) to 100 (normal).
The hmc has been validated over two groups of patients:
1) 322 children with JDM enrolled in a multinational
long-term outcome survey (Ravelli et al. AC&R
2010;62:63-72); 2) 294 children with DMG included in a
multinational study validation of the preliminary defini-
tion of clinical response led by PRINTO (Ruperto N.
AC&R 2008). Validation procedures were conducted by
comparing the correlation of the hmc, MMT and CMAS
with other conventional measures of JDM activity, physi-
cal function and damage. Correlations were computed by
means of the Spearman’s correlation coefficient and were
considered good, moderate, or poor when the rs was >
0.7, 0.4-0.7, or < 0.4, respectively. The ability to catch the
change over time was assessed by calculating the standar-
dized response mean (SRM) between 2 consecutive visits
(the SRM was considered satisfying if> 0.80).
Results
The Spearman’s correlations of hmc, MMT and CMAS
with other measures of disease activity and damage are
presented in the table 1.
Conclusion
We have developed a new hybrid measure of muscle
strength in JDM, which is more comprehensive than the
MMT and more feasible than the CMAS. Overall, the
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Hmc -0.54 -0.35 -0.58 -0.47 -0.68 -0.23 -0.64 -0.46 -0.52 -0.47 -0.44
MMT -0.58 -0.35 -0.58 -0.47 -0.69 -0.21 -0.62 -0.47 -0.54 -0.46 -0.43
CMAS -0.42 -0.28 -0.50 -0.40 -0.61 -0.27 -0.54 -0.40 -0.47 -0.43 -0.39
The SRM HMC, MMT, CMAS was, respectively, 0.90, 0.80 and 0.89.
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